Marker-free plasmids for biotechnological applications - implications and perspectives.

Area of Science:

• Biotechnology
• Molecular Biology
• Gene Therapy

Background:

• Nonviral gene therapy and DNA vaccines utilize plasmid DNA (pDNA) for disease treatment and prevention.
• Over 1800 clinical trials worldwide use pDNA vectors, with ~20% approved since 1989.
• Current pDNA vectors often contain antibiotic resistance genes, posing safety risks and stability issues.

Purpose of the Study:

• To review the implications of antibiotic marker-free plasmids in gene therapy and DNA vaccines.
• To explore the potential of marker-free selection approaches for improved pDNA vector performance.
• To discuss future perspectives for marker-free plasmids in biotechnology.

Main Methods:

• Literature review of antibiotic marker-free selection strategies for pDNA vectors.
• Analysis of safety, stability, and efficiency implications of marker-free plasmids.
• Exploration of biotechnological applications and future trends.

Main Results:

• Antibiotic resistance markers in pDNA vectors present safety risks and reduce efficiency.
• Marker-free selection methods address these drawbacks, enhancing plasmid stability and gene delivery.
• Development of novel marker-free approaches is crucial for advancing gene therapy and DNA vaccines.

Conclusions:

• Marker-free plasmids represent a significant advancement in nonviral gene delivery systems.
• These improved vectors hold promise for safer and more effective therapeutic and preventative strategies.
• Further research and development are essential for realizing the full biotechnological potential of marker-free plasmids.